Skip to contentpdufa.bio

zelicapavir RESOLVE

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

zelicapavir RESOLVE is an Enanta Pharmaceuticals Inc program in RSV (adults at high risk). Its next catalyst is a Readout in Q4 2027.

ENTA catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: RSV (adults at high risk). Sponsor: Enanta Pharmaceuticals Inc (ENTA). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027ENTA

Questions

When is zelicapavir RESOLVE's next FDA decision or readout?

The next tracked catalyst for zelicapavir RESOLVE is a Readout in Q4 2027.

What happened at zelicapavir RESOLVE's most recent FDA decision?

No FDA decision for zelicapavir RESOLVE is in our archive yet.

What is zelicapavir RESOLVE used for?

In our records zelicapavir RESOLVE is under review or in development for RSV (adults at high risk).

Who makes zelicapavir RESOLVE?

Enanta Pharmaceuticals Inc (ENTA).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.